A 'double-hit' stapled peptide inhibitor that targets two binding sites on talin simultaneously showed strong binding, excellent cell permeability, and effectively suppressed integrin activation in cells.
Double-hit + cell-permeableThe stapled peptide simultaneously targets two talin binding sites and penetrates cell membranes — combining multi-specificity with intracellular delivery in a single molecule.
What the researchers found
The stapled peptide S-TBS, derived from the talin-binding segment of RIAM, exhibited stronger binding to talin than the unmodified peptide and inhibited the talin-integrin interaction. X-ray crystallography confirmed S-TBS binds to the talin rod through the same interface as the natural TBS sequence.
Critically, the helical stapled peptide demonstrated excellent cell permeability (a common challenge for peptide drugs) and effectively suppressed integrin activation in living cells in a talin-dependent manner. The 'double-hit' approach — targeting two distinct sites with a single peptide — represents a novel design strategy for multi-specific peptidomimetic inhibitors.
Why it matters
Integrins are drug targets in cancer, thrombosis, autoimmune diseases, and fibrosis, but most existing integrin drugs target the extracellular binding face. This study opens a new therapeutic angle — blocking integrin activation from inside the cell by disrupting the talin-integrin signaling pathway. The stapled peptide technology also demonstrates that cell-permeable peptides can effectively modulate intracellular protein-protein interactions, expanding the druggable proteome.
How the study worked
Researchers designed the stapled peptide S-TBS by incorporating a molecular staple into the RIAM talin-binding segment to stabilize its helical structure. Binding affinity was measured through biophysical assays. The binding mode was confirmed by X-ray crystallography of the S-TBS:talin complex. Cell permeability was assessed using fluorescence-based assays. Functional inhibition of integrin activation was tested in cell-based assays measuring integrin activation states.
What this study cannot tell us
This is a proof-of-concept study with no animal testing. Cell-based assays demonstrate functional inhibition, but in vivo pharmacokinetics, biodistribution, and therapeutic efficacy remain unknown. The selectivity of S-TBS for talin versus other proteins was not comprehensively characterized. Long-term stability and potential toxicity of the stapled peptide were not assessed. Translation from cell-based to animal studies may reveal additional challenges.
How to read the evidence
This is a structural biology and cell biology study published in Structure. Crystal structure validation and cell-based functional assays provide strong mechanistic evidence, but all work is in vitro with no animal data.
When this study was published
Published in 2023, this study contributes to the rapidly growing stapled peptide therapeutics field and introduces a novel multi-site targeting strategy.
The bigger picture
Stapled peptides are an increasingly important class of therapeutics that bridge the gap between small-molecule drugs and biologics. By stabilizing peptide secondary structure with chemical staples, researchers can achieve cell permeability and protease resistance — overcoming two of the biggest challenges in peptide drug development. This work adds integrin signaling to the growing list of intracellular pathways targetable by stapled peptides, joining p53/MDM2, BCL-2 family, and others.
Questions still open
- Could this stapled peptide approach be developed into a drug for diseases driven by aberrant integrin activation, such as cancer metastasis?
- How does S-TBS selectivity compare across different talin isoforms and in tissues where integrin activation serves essential homeostatic functions?
- Could the 'double-hit' design principle be applied to other multi-site protein interactions to create more potent inhibitors?
Common questions
What is a stapled peptide and why is it useful?
Why target integrins from inside the cell instead of outside?
Read the original research
Inhibition of talin-induced integrin activation by a double-hit stapled peptide.
Structure (London, England : 1993), 31(8), 948-957.e3
Citation
Gao, Tong; Cho, Eun-Ah; Zhang, Pingfeng; Wu, Jinhua. (2023). Inhibition of talin-induced integrin activation by a double-hit stapled peptide.. Structure (London, England : 1993), 31(8), 948-957.e3. https://doi.org/10.1016/j.str.2023.05.016